Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Nonthaburi, Thailand.
Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Lao PDR.
Pain Physician. 2024 Sep;27(7):E761-E773.
Radiofrequency ablation (RFA) is a common secondary treatment recommended for facet joint-related chronic low back pain (CLBP). However, Thailand still lacks sufficient evidence of RFA's cost-effectiveness to support the decision to fund it.
To conduct a comparative economic evaluation of RFA and conservative treatment for CLBP patients over 16-month and 28-month time horizons in Thailand.
A full economic evaluation encompassing measurements of both health utilities and health costs.
Data were collected from 3 university hospitals in Bangkok, Thailand: King Chulalongkorn Memorial Hospital, Siriraj Hospital, and Ramathibodi Hospital.
The cost-utility analysis, which used the Markov model, was developed according to the Thai health technology assessment guidelines and compared RFA and the best supportive care from the societal perspective. In the study, the population consisted of patients who had endured low back pain for more than 3 months despite receiving conservative treatment. The results were presented as an incremental cost-effective ratio (ICER) in Thai Baht (THB)/quality-adjusted life year (QALY). Scenario and sensitivity analyses were conducted.
RFA was not cost-effective in Thailand when compared to conservative treatment, with a cost-effectiveness (CE) ratio of I$13,652 at all time horizons. The ICER of RFA was I$99,267 and I$52,380/QALY for the 16- and 28-month time horizons, respectively. In a scenario analysis in which RFA was repeated at 28 months and followed up to 52 months, the ICER was reduced to I$43,451. One-way sensitivity analysis showed that the ICER was most sensitive to the changes in utility parameters, the cost of RFA, and opportunity cost in the no-pain state.
The study uses primary data to derive the utility value and determine the costs. However, the limitation includes a relatively small sample size and a short follow-up time for parameter inputs.
This study, the first economic evaluation of RFA for CLBP in Asia, showed that RFA was not cost-effective in Thailand. Price negotiation is recommended to make the intervention more cost-effective before it is included in the benefit package.
射频消融 (RFA) 是一种常见的二级治疗方法,推荐用于治疗与小关节相关的慢性下腰痛 (CLBP)。然而,泰国仍然缺乏足够的证据证明 RFA 的成本效益,以支持为其提供资金的决定。
在泰国,对 RFA 与保守治疗超过 16 个月和 28 个月的 CLBP 患者进行成本效益比较。
这是一项全面的经济评估,包括对健康效用和健康成本的测量。
数据来自曼谷的 3 家大学医院:朱拉隆功纪念医院、诗里拉吉医院和玛希隆大学医院。
使用马尔可夫模型进行成本效用分析,该模型根据泰国卫生技术评估指南制定,并从社会角度比较了 RFA 和最佳支持性治疗。在该研究中,研究人群为那些在接受保守治疗后仍持续腰痛超过 3 个月的患者。结果以泰铢(THB)/质量调整生命年(QALY)表示的增量成本效益比(ICER)。进行了情景和敏感性分析。
在所有时间点,与保守治疗相比,RFA 在泰国均不具有成本效益,其成本效益(CE)比为 13652 泰铢(THB)/质量调整生命年(QALY)。RFA 的 ICER 在 16 个月和 28 个月时间点分别为 99267 泰铢(THB)和 52380 泰铢(THB)/QALY。在一项重复 28 个月并随访至 52 个月的情景分析中,ICER 降低至 43451 泰铢(THB)。单因素敏感性分析表明,ICER 对效用参数、RFA 成本和无疼痛状态下的机会成本的变化最为敏感。
该研究使用原始数据得出效用值并确定成本。然而,研究的局限性包括样本量相对较小和参数输入的随访时间较短。
这项在亚洲首次对 RFA 治疗 CLBP 的经济学评价显示,RFA 在泰国不具有成本效益。建议进行价格谈判,使该干预措施更具成本效益,然后再将其纳入福利包中。